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Short History of Vinyl Chloride
Regulation
Vinyl chloride (VC) is manufactured exclu-
sively for polymerization into polyvinyl chlo-
ride (PVC), a plastic used in construction,
packaging, electrical, and transportation indus-
tries; in household products such as ﬂooring,
water piping, videodiscs, and credit cards; and
in medical products such as disposable intra-
venous bags, tubing, and bedpans. Global PVC
production in 2002 was nearly 59 billion
pounds (27 million metric tons), valued at
approximately US$19 billion, with an average
annual growth rate of 3% since 1997 (Linak
and Yagi 2003). Approximately 15 billion
pounds (7 million metric tons) of PVC was
manufactured in the United States and Canada
in 2002, primarily for domestic use (Linak and
Yagi 2003). Pollution sources include produc-
tion and fabrication, incineration, and landﬁlls.
The ﬁrst experimental evidence of VC car-
cinogenicity was reported in 1969 (Viola PL,
unpublished data). Additional data were pub-
lished in 1971 (Viola et al. 1971), followed in
1974–1975 by disclosure of rare liver cancers
in workers (Creech and Johnson 1974;
Creech and Makk 1975; Maltoni 1974, 1975;
Maltoni et al. 1974). Upon release of these
data, the U.S. Occupational Safety and
Health Administration (OSHA) issued a
notice effective April 1975 that VC and PVC
production plants must reduce time-weighted
average workplace exposure levels from
500 ppm to 1 ppm, to provide adequate
worker protection (OSHA 1975).
When OSHA issued the new exposure
limit of 1 ppm, industry spokespeople issued
dire predictions of job loss and plant closures.
However, in < 2 years virtually all U.S. manu-
facturing plants were able to meet the new
standard while still maintaining rapid growth
of sales volume. This was accomplished
largely through better containment of
unpolymerized VC monomer and improved
exposure monitoring (OSHA 1975).
Early Suppression of Evidence
of Liver Damage
Industry leaders privately acknowledged that
the existing limit of 500 ppm was excessive
long before the OSHA standard (OSHA
1975). In 1959, internal industry experiments
had revealed micropathology in rabbit livers
after repeat exposures to 200 ppm VC
monomer (Markowitz and Rosner 2002),
causing Dow Chemical toxicologist V.K.
Rowe (1959) to admit privately to his counter-
part at B.F. Goodrich: 
We feel quite conﬁdent … that 500 ppm is going
to produce rather appreciable injury when inhaled
7 hours a day, five days a week, for an extended
period. As you can appreciate, this opinion is not
ready for dissemination yet and I would appreciate
it if you would hold it in conﬁdence but use it as
you see ﬁt in your own operations.
VC and PVC manufacturers also delayed
public release of ﬁndings of liver angiosarcoma
in VC-exposed rodents by Cesare Maltoni
(Markowitz and Tosner 2002). In late 1972,
the industry was briefed on Maltoni’s report of
primary cancers of both liver and kidneys
at exposures as low as 250 ppm, half the
500 ppm allowable exposure limit for workers.
However, in a meeting with government ofﬁ-
cials 8 months later in the summer of 1973,
industry representatives avoided any mention
of Maltoni’s ﬁndings (Markowitz and Rosner
2002). The public learned of the deadly haz-
ards of VC only in early 1974 through news-
paper reports of the deaths of three workers in
a B.F. Goodrich vinyl plant in Louisville,
Kentucky (Creech and Johnson 1974). Like
Maltoni’s experimental animals, the workers
had liver angiosarcoma.
Evidence of Nonliver Cancer
In addition to evidence of liver cancer, starting
in the 1970s the industry’s own studies
described excess cancers in nonliver sites,
including the respiratory system and the brain
(Tabershaw and Gaffey 1974). In a 1976
interofﬁce memo, Mitchell Zavon, a physician
with Ethyl Corporation, acknowledged that
At present, the epidemiological work has amply
demonstrated an association between high expo-
sures to VCM [vinyl chloride monomer] and an
increase in angiosarcoma of the liver, brain and
lung tumors. (Zavon 1976)
A scientific review by the International
Agency for Research on Cancer (IARC 1979)
found that 
Vinyl chloride is a human carcinogen. Its target
organs are the liver, brain, lung and haemo-lym-
phopoietic system … there is no evidence that
there is an exposure level below which no
increased risk of cancer would occur in humans.
A second IARC review in 1987 supported the
previous evaluation, citing more recent data
that, in addition to angiosarcoma of the liver,
VC caused hepatocellular carcinoma, brain
tumors, lung tumors, and malignancies of the
lymphatic and hematopoietic system (IARC
1987).
After the IARC evaluation, the industry
commissioned British epidemiologist Richard
Doll to review the previously published VC
epidemiology. Doll combined data from four
studies finding an aggregated excess risk of
brain cancer [29 observed vs. 19.54 expected,
standardized mortality ratio (SMR) = 148; con-
ﬁdence limits were not reported]; he reported
this as “not statistically signiﬁcant” and “noth-
ing to suggest that they are occupational in
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origin” (Doll 1988). Doll (1988) downplayed
risk of cancer in all sites other than liver, con-
cluding that 
[T]he mortality of the exposed men, other than
that due to angiosarcoma of the liver, is typical of
the normally healthy industrial worker—that is
not to say that no other hazard exists, but that the
effect of any other hazard is small.
Doll did not acknowledge funding
sources in his article (Doll 1988), but in a
legal deposition taken in a toxic tort case
brought by a worker dying of brain cancer,
Doll testiﬁed for the defendants that his 1988
report was conducted “on behalf of the
Chemical Manufacturers Association” for
which Doll received 12,000 British pounds
(~ US$21,000) as “a donation to a charity in
recompense” for his work (Doll 2000). The
charity Doll selected was the Green College at
Oxford, of which Doll is the founder and ﬁrst
warden (president).
Evidence of VC-associated brain cancer
continued to accumulate after 1988. A 1991
Chemical Manufacturers Association (CMA)–
sponsored follow-up study by Wong et al.
(1991) reported significant excess deaths
from cancer of the brain and central nervous
system [23 observed vs. 12.76 expected death;
SMR = 180; 95% confidence interval (CI),
114–271]. Wong et al. (1991) concluded that
“this update conﬁrms the excess in cancer of
the brain and [central nervous system].” In
addition, they reported significant excess
deaths from cancer of the liver and biliary tract
combined (37 observed vs. 6 expected deaths;
SMR = 641; 95% CI, 450–884), from liver
cancer excluding angiosarcoma (15 observed
vs. 3.0 expected deaths; SMR = 500, signiﬁ-
cant at 1% level), and from biliary tract cancer
excluding angiosarcoma (7 observed vs.
2.7 expected deaths; SMR = 259, signiﬁcant at
5% level).
Two years later, in a highly unusual rever-
sal, two of the original four authors published
a retraction, saying “we conclude that our
finding of an excess of brain cancer among
U.S. vinyl chloride workers reported earlier
was not likely related to the chemical”
(Wong and Whorton 1993). The Houston
Chronicle described the retraction and the
uses made of it:
Wong hadn’t received permission from the study’s
sponsor, the Chemical Manufacturers Association,
to publish his data—data that could be used
against the industry in lawsuits, that might alarm
workers and attract regulators. The unauthorized
publication provoked members of the CMA’s
Vinyl Chloride Panel and touched off a months-
long effort to persuade Wong to recant, docu-
ments show. Although Wong denies that he was
pressured, he changed his story on vinyl chloride,
declaring that the apparent excess of brain cancer
deaths among workers might well be the result of
“diagnostic bias”—better reporting and diagnosis
of the disease in industry than in the general
population …. Reprints of the Wong and Shah
letters were distributed among the chemical com-
panies and their attorneys. They are still cited by
defendants in brain cancer cases, and are used to
reassure workers about the safety of vinyl chloride
and polyvinyl chloride. (Morris 1998)
In 2000, for the fourth time, an industry-
sponsored study of VC epidemiology found an
excess of brain cancer among exposed workers
(Doll 1988; Mundt et al. 2000; Tabershaw
and Gaffey 1974; Wong et al. 1991). Mundt
et al. (2000) reported an increase in brain can-
cer among exposed workers (SMR = 142; 95%
CI, 100–197), with mortality from brain can-
cer showing the largest excess for study subjects
with the longest work history, based on
22 deaths (SMR = 177; 95% CI, 111–268).
Nonetheless, Mundt et al. (2000) concluded
that the “risk of mortality from brain cancer
has attenuated, but its relationship with expo-
sure to vinyl chloride remains unclear.”
U.S. EPA Reassessment of VC
Toxicology
Many of the U.S. Environmental Protection
Agency (EPA) assessments of regulated chemi-
cals are publicly available on its database, the
Integrated Risk Information System (IRIS),
which contains U.S. “EPA scientiﬁc consensus
positions on potential human health effects
from environmental contaminants” (U.S. EPA
1996). Although not a legal regulatory stan-
dard per se, such information is used by regula-
tors at the state and federal level and by others
worldwide in combination with exposure data
to set cleanup standards and various exposure
standards for air, water, soil, and food (Phibbs
2002). The widespread use of IRIS assessments
is demonstrated by the fact that the database
receives more than half a million visits
monthly, from > 50 countries (IRIS 2005).
In 1994, the CMA’s Vinyl Chloride Panel
initiated plans to work with the U.S. EPA on
its IRIS assessment of VC. H.C. Shah, the
industry panel manager, confirmed that the
U.S. EPA “expressed an interest in working
with industry to develop a scientiﬁcally-sound
vinyl chloride risk assessment” (Shah 1994a,
1994b). At the meeting, CMA-sponsored sci-
entists made presentations to the U.S. EPA
on both the CMA-sponsored epidemiology
and a prepublication risk model (Reitz and
Gargas 1994; Shah 1994a, 1994b). The
model, a physiologically based pharmaco-
kinetic (PBPK) model, was designed to quan-
titatively express the relationship between
external exposure to VC and internal dose at
the liver, taking into account absorption, dis-
tribution, metabolism, and elimination of VC
and its metabolites.
Although internal documents demon-
strate that the U.S. EPA and the VC industry
had been in joint discussions on an updated
IRIS assessment of VC since 1994 (Shah
1994a, 1994b), it was not until 1996 that the
U.S. EPA issued a public notice inviting sub-
missions of technical information for VC and
10 other industrial chemicals to be assessed
for the IRIS database (U.S. EPA 1996).
U.S. EPA Standard Based on
Overall Risk of Liver Cancer,
Not Overall Cancer Risk
As noted above, as early as 1994 the VC
industry had been promoting PBPK models
for use by the U.S. EPA in its VC assessment.
Two such models were presented to the U.S.
EPA for its VC risk assessment. The models
predicted that VC was 150-fold less (Reitz and
Gargas 1994; Reitz et al. 1996) and 80-fold
less (Clewell et al. 1995, 2001) potent as a car-
cinogen than values used at the time for
environmental decision making, implying that
pollution and cleanup standards could be
weakened signiﬁcantly. The ﬁnal IRIS assess-
ment relied on the Clewell model (Clewell et al.
1995, 2001), but with adjustments such that
VC was estimated by the U.S. EPA to be
10-fold less potent as a carcinogen. Although
the model was developed using only liver angio-
sarcoma tumor data, cancer estimates for the
U.S. EPA assessment were revised to include
all liver tumors but exclude all nonliver tumors
(U.S. EPA 2000a). Because exposure was not
adequately characterized in the epidemiology
studies, the U.S. EPA cancer potency estimates
were based on animal bioassay data.
Both models were designed to model only
VC’s effects on the liver, despite scientiﬁc con-
sensus that it is a multisite carcinogen in
humans and experimental animals (Byren et al.
1976; Cooper 1981; Drew et al. 1983; Feron
et al. 1979; Hagmar et al. 1990; IARC 1979,
1987; Infante 1981; Maltoni and Lefemine
1975; Maltoni et al. 1981; Monson et al.
1974; Mundt et al. 2000; Smulevich et al.
1988; Tabershaw and Gaffey 1974; Wagoner
et al. 1980; Waxweiler et al. 1976, 1981;
Weber et al. 1981; Wong and Whorton 1993;
Wong et al. 1991; Wu et al. 1989).
VC administered orally or by inhalation to
mice, rats, and hamsters produced tumors in
the mammary gland (Feron et al. 1981; Hong
et al. 1981; IARC 1987), leading Clewell et al.
(1995) to suggest that 
it seems reasonable that the evidence of increased
mammary tumor incidence from VC should be
considered at least qualitatively during risk manage-
ment decisions regarding potential human
VC exposure.
In its May 1999 draft VC assessment, the
U.S. EPA had proposed to apply a protective
3-fold factor to adjust for VC’s possible
induction of nonliver tumors (U.S. EPA
1999a). However, in a letter to the U.S. EPA,
chemical manufacturers protested that [T]he available epidemiological evidence does not
support an association between vinyl chloride
exposure and human cancer except angiosarcoma
of the liver. The ill-advised three-fold uncertainty
factor introduced by EPA to account for possible
tumor induction at such sites can therefore be
eliminated. (Price 1999)
In response, the U.S. EPA ﬁnal VC assessment
completely eliminated the protective factor it
had originally included (U.S. EPA 2000a). In
the same letter to the U.S. EPA, chemical
manufacturers disputed the U.S. EPA state-
ment that there is “suggestive epidemiological
evidence that cancer of the brain, lung, and
lymphopoietic system are associated with
exposure,” saying it “should be deleted from
the ﬁnal review” (Price 1999). The U.S. EPA
complied (U.S. EPA 2000a).
The U.S. EPA assessment’s exclusion of
risks to organs other than liver is striking. The
U.S. EPA justifies this approach on two
grounds: first, relying on the conclusions of
Richard Doll that evidence for induction of
nonliver tumors is weak (Doll 1988); and sec-
ond, suggesting that the liver is the most sensi-
tive end point and therefore regulatory
standards protective of liver cancer would ade-
quately protect all other sites from cancer risk
(U.S. EPA 2000b). However, this limited view
precludes the U.S. EPA from developing a
standard based on an assessment of the total
cancer risk to all organs from VC exposure, as
required by U.S. EPA guidelines for calculating
carcinogenic risk (U.S. EPA 1999b, 2005).
Downplaying risk to nonliver cancer sites
leaves the public and exposed workers inade-
quately informed of the health threat posed
by exposure to VC-containing products,
processes, and pollution. Medical professionals
are less likely to suspect a link to VC exposures
in patients with nonliver cancers, and thus
causal links are more likely to be overlooked.
Downplaying of nonliver cancer risks by the
U.S. EPA may also have important implica-
tions in litigation of compensation cases,
because claims for cancers at sites other than
the liver are vigorously disputed in the courts.
Peer Review Reﬂects Industry
Participation
The U.S. EPA’s external peer review process
is intended to ensure that a scientifically
credible assessment is produced. However, at
least 7 of the 19 external peer reviewers of the
VC assessment were chemical industry
employees and consultants, 4 were govern-
ment representatives, and none represented
unions or public interest groups (U.S. EPA
2000b). This committee accepted the asser-
tion by the U.S. EPA that human exposure
limits based on liver cancer would be suffi-
ciently protective against cancer developing
in other tissues. The committee rejected the
use of any protective adjustment factor to
account for the possibility of nonliver cancer
risk (U.S. EPA 2000a). As noted above, the
ﬁnal assessment made no adjustments for the
possibility of cancer at nonliver sites.
The ﬁnal VC assessment currently posted
on the IRIS database (U.S. EPA 2000b) assigns
a cancer risk from VC inhalation (8.8 × 10–6
risk per µg/m3; an excess of 8.8 cases per 1 mil-
lion people exposed over a lifetime to an aver-
age of 1 µg/m3 VC) that is about 10-fold lower
than the previous assessment (8.4 × 10–5 risk
per µg/m3; an excess of 84 cases per 1 million
people exposed over a lifetime to an average of
1 µg/m3 VC). As a result, allowable pollution
levels may increase by 10-fold.
The Trend to Incorporate
Industry Participation in
U.S. EPA Scientiﬁc
Assessments
For some of the most widespread and toxic
chemicals under regulation, the manufactur-
ers are generating much of the data (often
unpublished) used for risk assessment and are
working closely with the U.S. EPA to evaluate
available data and produce risk assessments.
Unfortunately, the efforts of the regulated
industries often outweigh the ability of the
public, unions, and public interest groups to
participate in developing regulations. In a
2002 interview, Paul Gilman, at that time the
science adviser to U.S. EPA Administrator
Whitman, expressed dissatisfaction with the
industry submissions for IRIS: 
[I]t is taking staff as much or more time to work
with the outside parties as it does to develop in-
house toxicological reviews, Gilman said. To date,
the process has not saved the time or resources it
was designed to save. (Phibbs 2002)
Nonetheless, in late August 2004, the U.S.
EPA announced changes to its pesticide review
process “that would give industry officials
greater input in the science behind its risk
reviews … in an effort to reduce the agency’s
review times” (Inside EPA 2004). The trend
toward increasing industry participation
allows corporate interests with products under
regulation to more effectively recommend
acceptable limits of public exposure to their
own products and wastes, while placing an
unrealistic burden on the U.S. EPA scientists
and the public to provide adequate peer
review and oversight. Public confidence is
undermined when commercial interests,
instead of scientiﬁc evaluations, shape public
health policy.
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